SEC Tracker
Get the app

Immunic IMUX

Immunic Q2 FY25: net loss $26.8M; diluted EPS −$0.20

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Immunic reported for Q2 FY25, the quarter ended Jun 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$26.8MAgainst −$21.4M in Q2 FY2410-Q income statement, on EDGAR
  2. Diluted EPS−$0.20Against −$0.21 in Q2 FY2410-Q income statement, on EDGAR
  3. Cash and cash equivalents$55.3M−31% from $79.7M in Q2 FY2410-Q balance sheet, on EDGAR
  4. Cash from operations−$24.6MAgainst −$17.0M in Q2 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Immunic files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Anixa Biosciences ANIX public float $85M, Apr 30, 2025, over 18 months old
  2. Filana Therapeutics FLNA public float $87M, Jun 30, 2025
  3. Oramed Pharmaceuticals ORMP public float $78M, Jun 30, 2025
  4. GENELUX GNLX public float $89M, Jun 30, 2025
  5. Inovio Pharmaceuticals INO public float $74M, Jun 30, 2025